Clinical trial
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
NCT00534989 is registered in ClinicalTrials.gov with King Faisal Specialist Hospital & Research Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
- Lead sponsor
- King Faisal Specialist Hospital & Research Center
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- December 31, 2013
- Enrollment
- 10 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.